Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    strive anti-jcv
Show Display Options
Rank Status Study
1 Recruiting Observational Study of Tysabri® in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus (JCV) Antibody Negative Participants
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:

Indicates status has not been verified in more than two years